Analyst Reco. IN8bio, Inc.

Equities

INAB

US45674E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.19 ^USD	+14.42%		+17.82%	-13.77%

May. 24	IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	MT
May. 13	HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on IN8bio to $12.50 From $14, Keeps Buy Rating	May. 13	MT
Laidlaw Initiates Coverage on IN8bio With Buy Rating, $7.50 Price Target	Mar. 18	MT
JonesTrading Starts IN8bio With Buy Rating, $5 Price Target	Mar. 13	MT
EF Hutton Initiates IN8bio at Buy With $8 Price Target	23-03-29	MT
B. Riley Downgrades IN8bio to Neutral From Buy, Notes Limited Catalysts, Cash; Lowers Price Target to $3 From $9	22-11-11	MT
HC Wainwright Starts IN8bio at Buy with $14 Price Target	22-08-30	MT
B. Riley Lowers IN8bio's Price Target to $9 from $19 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
IN8BIO : Mizuho Securities Starts IN8bio at Buy With $12 Price Target	21-08-24	MT
IN8BIO : B. Riley Starts IN8bio at Buy with $19 PT, Ascribes Value to Glioblastoma Multiforme Program	21-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer